CD95L/FasL and TRAIL in Tumour Surveillance and Cancer Therapy
Author:
Publisher
Springer US
Link
http://link.springer.com/content/pdf/10.1007/0-387-26283-0_7
Reference139 articles.
1. Ambar, B.B. et al. (1999). Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum. Gene Ther. 10: 1641–1648.
2. Almasan, A. and Ashkenazi, A. (2003). Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14: 337–48.
3. Aoki, K. et al. (2000). Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy. Mol. Ther. 1: 555–565.
4. Aoki, K. et al. (2001). Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat. Immunol. 2: 333–337.
5. Arai H. et al. (1997). Inhibition of the alloantibody response by CD95 ligand. Nat. Med. 3: 843–848.
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Signaling controversy and future therapeutical perspectives of targeting sphingolipid network in cancer immune editing and resistance to tumor necrosis factor-α immunotherapy;Cell Communication and Signaling;2024-05-02
2. Small EV in plasma of triple negative breast cancer patients induce intrinsic apoptosis in activated T cells;Communications Biology;2023-08-04
3. Regulation of the tumor immune microenvironment by cancer-derived circular RNAs;Cell Death & Disease;2023-02-16
4. Vesicle Induced Receptor Sequestration: Mechanisms behind Extracellular Vesicle‐Based Protein Signaling;Advanced Science;2022-03
5. Protein Kinase D3 Promotes the Reconstruction of OSCC Immune Escape Niche Via Regulating MHC-I and Immune Inhibit Molecules Expression;Journal of Immunotherapy;2021-09-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3